Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz model

Cross-border biotech Anji Pharma closed $70 million in Series B funding to advance a drug pipeline that includes metabolic and cancer drugs. The biotech’s business model of finding promising drugs and forming subsidiaries to develop them is similar to approaches taken by Roivant Sciences and BridgeBio Pharma, among others.

Sinopharm launches Phase III trial of inactivated-virus vaccine in Abu Dhabi

The Beijing company said it selected the United Arab Emirates because of its ethnic diversity, which will enable it to determine the feasibility of taking its program global. It claims that its study is the first Phase III inactivated vaccine trial, but another Chinese firm has also launched one in Brazil.